Primary intravenous paclitaxel and platinum chemotherapy for high-risk Stage I epithelial ovarian carcinoma Journal Article
| Authors: | Chi, D. S.; Waltzman, R. J.; Barakat, R. R.; Spriggs, D. R. |
| Article Title: | Primary intravenous paclitaxel and platinum chemotherapy for high-risk Stage I epithelial ovarian carcinoma |
| Abstract: | Objective: To evaluate the efficacy of intravenous (IV) paclitaxel and platinum chemotherapy in patients with high-risk Stage I epithelial ovarian carcinoma. Methods: We performed a retrospective chart review of all patients with Stage I ovarian cancer treated at our institution between March 1993 and June 1995. Results: Twenty patients received adjuvant paclitaxel-containing chemotherapy for Stage I ovarian carcinoma after comprehensive surgical staging. Five patients (25%) had Stage IA disease and 15 patients (75%) had Stage IC disease. Tumor grades were: 1, five patients (25%); 2, nine patients (45%); and 3, six patients (30%). Histologic cell types were: clear-cell, ten (50%); endometrioid, five (25%); mucinous, three (15%); and serous, two (10%). Nineteen patients (95%) were treated with IV paclitaxel and platinum chemotherapy. One patient (5%) received IV paclitaxel alone. Eighteen patients (90%) had five cycles of chemotherapy, while two patients (10%) had three. The 96 total cycles were associated with nine episodes (9%) of significant toxicity: fever, four (4%); severe nausea and vomiting, two (2%); Clostridium difficile enteritis, one (1%); congestive heart failure, one (1%); and anemia, requiring blood transfusion, one (1%). With a median follow-up of 36 months (range 24-50 mos), all 20 patients are alive, and 19 (95%) are disease-free. The one patient (5%) treated with IV paclitaxel alone developed an abdominal recurrence 22 months after diagnosis. Conclusion: Primary IV paclitaxel and platinum chemotherapy in patients with high-risk Stage I epithelial ovarian carcinoma is reasonably well tolerated and may improve survival. Larger studies with long-term follow-up are needed. |
| Keywords: | adult; cancer survival; clinical article; treatment outcome; aged; disease-free survival; middle aged; retrospective studies; cancer recurrence; cisplatin; drug efficacy; paclitaxel; chemotherapy, adjuvant; cancer staging; follow-up studies; antineoplastic agent; neoplasm staging; adenocarcinoma; ovarian neoplasms; carboplatin; anemia; nausea; vomiting; antineoplastic combined chemotherapy protocols; retrospective study; histology; high risk patient; fever; ovary carcinoma; blood transfusion; enteritis; clostridium difficile; congestive heart failure; drug evaluation; humans; human; female; article |
| Journal Title: | European Journal of Gynaecological Oncology |
| Volume: | 20 |
| Issue: | 4 |
| ISSN: | 0392-2936 |
| Publisher: | I R O G Canada, Inc |
| Date Published: | 1999-07-01 |
| Start Page: | 277 |
| End Page: | 280 |
| Language: | English |
| PUBMED: | 10475122 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 16 August 2016 -- Source: Scopus |
Citation Impact
Related MSK Work